183 related articles for article (PubMed ID: 32467600)
1. The association of diabetes with risk of prostate cancer defined by clinical and molecular features.
Feng X; Song M; Preston MA; Ma W; Hu Y; Pernar CH; Stopsack KH; Ebot EM; Fu BC; Zhang Y; Li N; Dai M; Liu L; Giovannucci EL; Mucci LA
Br J Cancer; 2020 Aug; 123(4):657-665. PubMed ID: 32467600
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
3. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
[TBL] [Abstract][Full Text] [Related]
4. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.
Allott EH; Ebot EM; Stopsack KH; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Ahearn TU; Gerke TA; Downer MK; Rider JR; Freedland SJ; Lotan TL; Kantoff PW; Platz EA; Loda M; Stampfer MJ; Giovannucci E; Sweeney CJ; Finn SP; Mucci LA
Clin Cancer Res; 2020 Mar; 26(5):1086-1093. PubMed ID: 31754047
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
6. Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.
Feng X; Zhou CK; Clish CB; Wilson KM; Pernar CH; Dickerman BA; Loda M; Finn SP; Penney KL; Schmidt DR; Vander Heiden MG; Giovannucci EL; Ebot EM; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):1000-1008. PubMed ID: 33627383
[TBL] [Abstract][Full Text] [Related]
7. Height, Obesity, and the Risk of
Graff RE; Ahearn TU; Pettersson A; Ebot EM; Gerke T; Penney KL; Wilson KM; Markt SC; Pernar CH; Gonzalez-Feliciano AG; Song M; Lis RT; Schmidt DR; Vander Heiden MG; Fiorentino M; Giovannucci EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):193-200. PubMed ID: 29167279
[No Abstract] [Full Text] [Related]
8. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
10. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
11. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
12. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
[TBL] [Abstract][Full Text] [Related]
13.
Haney NM; Faisal FA; Lu J; Guedes LB; Reuter VE; Scher HI; Eastham JA; Marchionni L; Joshu C; Gopalan A; Lotan TL
J Urol; 2020 Feb; 203(2):344-350. PubMed ID: 31502941
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
15. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
16. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
17. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
Graff RE; Judson G; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
Prostate; 2017 May; 77(6):647-653. PubMed ID: 28102015
[TBL] [Abstract][Full Text] [Related]
18. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.
Liu R; Zhou J; Xia S; Li T
Clin Transl Oncol; 2020 May; 22(5):694-702. PubMed ID: 31359337
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
20. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
